IHAM
Integral Health Asset Management Portfolio holdings
AUM
$1.07B
This Quarter Return
+14.97%
1 Year Return
+40.53%
3 Year Return
+328.04%
5 Year Return
+535.34%
10 Year Return
–
AUM
$493M
AUM Growth
+$493M
(+1.3%)
Cap. Flow
-$15.6M
Cap. Flow
% of AUM
-3.17%
Top 10 Holdings %
Top 10 Hldgs %
33.64%
Holding
86
New
21
Increased
22
Reduced
21
Closed
22
Top Buys
| 1 |
Baxter International
BAX
|
$16.2M |
| 2 |
Boston Scientific
BSX
|
$13.6M |
| 3 |
Biogen
BIIB
|
$13.4M |
| 4 |
Cardinal Health
CAH
|
$13.3M |
| 5 |
Neurocrine Biosciences
NBIX
|
$9.56M |
Top Sells
| 1 |
Eli Lilly
LLY
|
$15.5M |
| 2 |
AstraZeneca
AZN
|
$15.5M |
| 3 |
CCXI
ChemoCentryx, Inc.
CCXI
|
$14.2M |
| 4 |
Elevance Health
ELV
|
$12.6M |
| 5 |
DexCom
DXCM
|
$12.4M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Guardant Health
GH
$8.41B
| $24.2M | 4.71% | 450,000 +64,709 | +17% | +$3.48M |
|
|
2
Elevance Health
ELV
$71.8B
| $18.2M | 3.53% | 40,000 -27,840 | -41% | -$12.6M |
|
3
Centene
CNC
$14.3B
| $17.5M | 3.4% | 225,000 -125,000 | -36% | -$9.73M |
|
4
Cytokinetics
CYTK
$4.23B
| $17M | 3.29% | 350,000 -175,000 | -33% | -$8.48M |
|
|
5
Baxter International
BAX
$12.7B
| $16.2M | 3.14% | +300,000 | New | +$16.2M |
|
6
Merck
MRK
$210B
| $15.9M | 3.09% | 185,000 +80,631 | +77% | +$6.94M |
|
7
Envista
NVST
$3.52B
| $14.4M | 2.8% | 440,000 +53,835 | +14% | +$1.77M |
|
8
CRISPR Therapeutics
CRSP
$4.71B
| $14.4M | 2.79% | 220,000 +139,990 | +175% | +$9.15M |
|
9
Alnylam Pharmaceuticals
ALNY
$58.5B
| $14M | 2.72% | 70,000 +23,034 | +49% | +$4.61M |
|
|
SAGE
10
DELISTED
Sage Therapeutics
SAGE
| $14M | 2.72% | 357,000 -55,257 | -13% | -$2.16M |
|
|
11
Boston Scientific
BSX
$156B
| $13.6M | 2.63% | +350,000 | New | +$13.6M |
|
12
Relay Therapeutics
RLAY
$619M
| $13.4M | 2.61% | 600,000 +163,738 | +38% | +$3.66M |
|
|
13
Biogen
BIIB
$19.4B
| $13.4M | 2.59% | +50,000 | New | +$13.4M |
|
|
14
Cardinal Health
CAH
$35.5B
| $13.3M | 2.59% | +200,000 | New | +$13.3M |
|
15
CVS Health
CVS
$92.8B
| $12.4M | 2.41% | 130,000 -10,898 | -8% | -$1.04M |
|
16
Zentalis Pharmaceuticals
ZNTL
$122M
| $11.9M | 2.31% | 550,000 +209,757 | +62% | +$4.54M |
|
17
Perrigo
PRGO
$3.27B
| $11.4M | 2.22% | 320,000 +137,355 | +75% | +$4.9M |
|
18
McKesson
MCK
$85.4B
| $10.2M | 1.98% | 30,000 -11,748 | -28% | -$3.99M |
|
|
19
Neurocrine Biosciences
NBIX
$13.8B
| $9.56M | 1.86% | +90,000 | New | +$9.56M |
|
20
Sanofi
SNY
$121B
| $9.51M | 1.85% | 250,000 -100,000 | -29% | -$3.8M |
|
21
BioMarin Pharmaceuticals
BMRN
$11.2B
| $9.07M | 1.76% | 107,000 -19,286 | -15% | -$1.63M |
|
22
PTC Therapeutics
PTCT
$3.92B
| $8.18M | 1.59% | 163,000 +58,344 | +56% | +$2.93M |
|
23
uniQure
QURE
$896M
| $8.12M | 1.58% | 433,000 +79,894 | +23% | +$1.5M |
|
|
24
Eli Lilly
LLY
$657B
| $8.08M | 1.57% | 25,000 -48,059 | -66% | -$15.5M |
|
25
Akero Therapeutics
AKRO
$3.74B
| $7.83M | 1.52% | 230,000 -58,058 | -20% | -$1.98M |
|